

(Translated)

Minutes of the Annual General Meeting of Shareholders for the year 2026
of
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

An English version of the minutes of meeting is translated from Thai language. In the event of conflict or difference in interpretation in two languages, the Thai language minutes of meeting shall prevail.

Time and place

The Meeting was held on 21 April 2026 at 10.00 AM by means of electronic meeting (E-AGM) pursuant to the Emergency Decree on Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings via Electronic Means, B.E. 2563 (2020).

Attending Directors for the Meeting (The Company had 11 directors, with 10 directors attended accounted for 90.9% attendance)

- | | | |
|----|-----------------------------------|---|
| 1. | Ms. Sopawadee Lertmanaschai | Independent Director, Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee |
| 2. | Pharm. Vinit Usavakidviree | Independent Director and Member of the Audit Committee |
| 3. | Asst. Prof. Lalita Hongratanawong | Independent Director, Member of the Audit Committee and Chairman of the Nomination and Remuneration Committee |
| 4. | Mr. Natthawut Viboonpatanawong | Independent Director and Chairman of the Risk Management Committee |
| 5. | Mr. Tawat Kitkungvan | Director and Member of the Nomination and Remuneration Committee |
| 6. | Mrs. Jintana Suntipisud | Director and Chairman of the Executive Committee |
| 7. | Dr. Sittichai Daengprasert | Director, Member of the Risk Management Committee, Member of the Executive Committee, Group President and Executive Vice President of Business Strategy and Innovation (Acting) |
| 8. | Mr. Pissanu Daengprasert | Director, Member of the Executive Committee and President (CEO) |

(Translated)

9. Ms. Jirada Daengprasert Director, Member of the Nomination and Remuneration Committee, Member of the Executive Committee and Executive Vice President of Finance and Accounting (CFO) and Executive Vice President of Manufacturing and Operations (Acting)
10. Mr. Sorasit Daengprasert Director, Member of the Risk Management Committee, Member of the Executive Committee and Executive Vice President of Sales and Marketing

Absent Director for the Meeting due to a Prior Commitment

1. M.D. Thongchai Thavichachart Chairman of the Board of Directors and Independent Director

Attending Management for the Meeting

1. Mr. Kriangkrai Rungruangthaweekul Member of the Executive Committee and Vice President of Finance
2. Pharm. Nongnuch Cheawpattayakorn Member of the Executive Committee and Quality Assurance Director
3. Mr. Danaisuan Kunarosombat Member of the Executive Committee and Director of Plant Operations

Attending Auditor from KPMG Phoomchai Audit Ltd. for the Meeting

1. Ms. Kanokorn Phooripanyawanit
2. Ms. Papawadee Sanprom

Attending Legal Advisor for the Meeting

1. Mr. Pichit Rattanabhorn

Preliminaries

Ms. Patcharaphon Puaekbutr welcomed the shareholders to the Annual General Meeting of Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited for the year 2026 (the "Meeting"). She then explained the details of this Meeting that it was a meeting via electronic media, a system having the standard consistent with the conditions and procedures prescribed in the Emergency Decree on

(Translated)

Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). In this meeting, the Company used electronic meeting system provided by OJ International Company Limited, which has been certified by Electronic Transactions Development Agency (ETDA). Eligible attendees at the Meeting must complete self-verification in accordance with the methods prescribed by the Company and agree to comply with the requirements for attending the Annual General Meeting of Shareholders for the year 2026. This was to facilitate the shareholders and reduce their travel burden and to make the most of technology.

For the sake of transparency and to comply with the best practices for a shareholders' meeting, the Company invited Mr. Pichit Rattanabhorn, the Company's legal advisor, to witness the vote counting.

The moderator declared to the Annual General Meeting of Shareholders for the year 2026 of the Company that there were 37 shareholders attending (in person and by proxy), representing an aggregate of 324,782,308 shares, equivalent to 68.44% of the total number of issued shares, and therefore constituting a quorum pursuant to Article 38 of the Company's Articles of Association.

Ms. Sopawadee Lertmanaschai, Independent Director and Chairman of the Audit Committee, who presided as the chairman of the Meeting (the "Chairman"), thanked to the shareholders and opened the Annual General Meeting of Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited for the year 2026. And then she assigned Ms. Patcharaphon Puaekbutr to act as moderator.

Prior to follow meeting agendas, the moderator briefly explained to the shareholders the voting procedure and details of the meeting practice. The voting procedure shall be in accordance with the Company's Articles of Association, i.e., one share carries one vote. In each agenda item, shareholders are able to vote "Approved", "Disapproved" or "Abstained". The system will allow one minute of voting per agenda item. Any shareholder failing to press vote in any agenda item shall be deemed to have "Approved" in such agenda item. With respect to vote counting, only shareholders' votes in "Disapproved" and "Abstained" will be counted and then deducted from the total number of votes of the attending shareholders, which results in the remainder being considered approval votes for such agenda item.

- In general, the approval resolution requires a majority vote of the shareholders attending the Meeting and casting their votes. If the votes are ties, the Chairman shall cast another vote as a final vote.
- Agenda item on election of directors shall be approved by the majority vote of the shareholders attending the Meeting and casting their votes. Whereby, the votes shall be conducted separately for each of director.
- Agenda item on director's remunerations shall be approved by the votes not less than two-thirds of all votes of the shareholders who attend the meeting.

(Translated)

- In case of shareholders who granted a proxy and has already specified votes in each agenda, the system shall count the votes as the shareholders specified. Therefore, the proxy shall not cast the votes in the voting system.

After that, the staff will gather all votes from the voting system. Voting is unavailable in any agenda item for acknowledgment. Once voting is closed in any agenda item, the shareholders will no longer submit a vote or change the vote in that agenda item.

If any shareholder logs out from the system during the Meeting, the system will exclude the said shareholder's vote in that certain agenda item from the base for calculation to conform with the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). However, the shareholder may log in to attend the Meeting at all times until the Meeting is adjourned.

Furthermore, as the voting procedure for this Meeting is via an online system, void ballots shall not occur, except for the case of votes in a proxy form submitted to the Company in advance. Any ballot which (1) is marked in more than one box or (2) does not show true intention of the voter in regard to the voting will be deemed as a void ballot. If any shareholder or proxy delays in attending the Meeting via electronic means, the shareholder or proxy may register and attend the Meeting but will be eligible to vote only in the remaining agenda items. The Company will report to the Meeting details of the voting results for each agenda item after completion of consideration and voting in each agenda item. Nonetheless, if vote counting in certain agenda item takes more time than usual, the Company will proceed with consideration of the following agenda item to enable continuation of the Meeting, and once the staff have finished vote counting, the voting results will be immediately reported to the Shareholders' Meeting. In addition, the Company recorded this meeting by mean of video.

Prior to cast the vote in each agenda, the Company allows any shareholder who attend the Meeting and wishing to raise questions or provide suggestions related to such agenda, as appropriate, for one minute. The shareholders could do in 2 ways i.e. (a) via chat box and (b) via audio and visual through VDO Conference.

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to propose meeting agendas and nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2026, during 16 September 2025 to 1 November 2025. However, neither meeting agenda nor candidate was proposed and nominated by the shareholders.

(Translated)

Agenda 1 To Acknowledge the Annual Report for the Year 2025

The Chairman assigned Dr. Sittichai Daengprasert; Group President, to report the Company's performance for the year 2025.

Group President informed the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider the report of the Board of Directors showing the Company's performance in the previous year.

The Board of Directors has already prepared the Directors' Report which described the Company's performance for the year 2025 as detailed in the Annual Registration Form (56-1 One Report) for the year 2025 which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, that Board of Directors had approved and deemed it appropriate to propose the Company's Annual Report for the year 2025 to the Shareholders' Meeting for acknowledgement.

Report on Anti-Corruption Activities

The Company has determined various charters and policies in order to provide understanding to directors, executives and employees and applied them appropriately. These included good corporate governance, duty and care to stakeholders and anti-corruption. Especially, the Company had anti-corruption policy to express intention and determine guidelines for anti-corruption, also build up good culture in business's operations. The Company expects that such policy will create assurance to stakeholders and regulators. The Company prohibited directors, executives, and employees to participate or involve with all activities that might cast to corruption, both direct and indirect ways. For instance, bribery, give or receive unusual entertainment and/or gift. In addition, the Company set aside measures over whistleblowing channels, investigations, punishments, protection of whistleblowers and protection to persons who refuse corruption.

In 2025, the Company provided training to directors, executives, and employees in relation to anti-corruption by mean of self-learning through e-learning and all personnels have signed for acknowledgement over the measures. Furthermore, the Company had no claim arose from corruption.

The Company is currently studying information about Thai Private Sector Collective Action Against Corruption and preparing assessment form under Thai Private Sector Collective Action Against Corruption for certifying as member of the collective action.

Business Overview

In overview, the Company aims to strengthen in all areas through value chain to be leader in the industry. Also, the Company aims to expand group of customers continually, which comprises

(Translated)

1. Product research and development, scientific testing in laboratory and training to entrepreneurs, operated by CDIP (Thailand) Public Company Limited.
2. Manufacturing in basis of OEM, Own Brand with brand name “Suphap Osot” operated by the Company, manufacturing for small orders operated by Caresutic Company Limited, and Hemodialysis operated by Grace Water Med Public Company Limited
3. Distributing of goods through traditional shop, TV Shopping and vending machines
4. Providing traditional Thai medical treatment via Suphap Osot Polyclinic

Significant Developments in 2025

The Company had significant development in dietary supplement; namely “Suphap Osot”, by having more presenters and marketing medias through buses and online channels, which created good acceptance from customers. The Company also increased production capacity to create variety of products with high quality to the market.

The Group expanded hemodialysis business through listing in LiVE Exchange Market with total consideration of Baht 26.34 million.

The Company was awarded “Very Good” rating from IOD about Corporate Governance for listed companies and “Excellent” rating from TIA about organising AGM.

Business Plan for 2026

The Company joined JUMP+ program; organised by the Stock Exchange of Thailand, to enhance sustainable growth with 15% target CAGR of revenue growth p.a. during 2026-2028 and get through the crisis via 6 strategies for sustainable growth as follow:

1. **Elevated Own Brand** through increasing visibility via marketing activities and enter into online market
2. **Growing OEM and Beyond** through securing and expanding OEM customer base, innovation development and enhance customer’s experience via effective system
3. **International Expansion** through building team for international growth and developing appropriate business model to create strategic partners
4. **Business Expansion Along Value Chain** through increasing partners and networks for new business, improving production efficiency and quality control, together with business growth along value chain by new income stream
5. **Capture Opportunities Though Investments & Partnerships** by investing in healthcare business aligns with business strategies and creating long-term value-added in investment portfolio

(Translated)

6. **Operational Efficiency & Cost Optimisation** through introducing automation and production capacity management, as well as materials cost and energy reductions

Group President then gave the shareholders an opportunity to raise questions about the Company's performance for the year 2025.

No shareholder had any question about the Company's performance for the year 2025.

The Meeting acknowledged the Annual Report for the year 2025.

Agenda 2 **To Consider Approving the Financial Statements for the Year Ended 31 December 2025**

The Chairman assigned Ms. Jirada Daengprasert; Executive Vice President of Finance and Accounting (CFO), to report the Company's financial statements for the year ended 31 December 2025.

Executive Vice President of Finance and Accounting (CFO) explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider approving the statement of financial position and statement of comprehensive income at the end of the previous fiscal year, and Article 57 of the Company's Articles of Association and Section 112 of the Public Limited Companies Act, B.E. 2535 (1992), prescribes that the Board of Directors must cause the balance sheet (statement of financial position) and the profit and loss account (statement of comprehensive income) at the end of the Company's fiscal year to be made and propose to the Shareholders' Meeting for consideration and approval in the Annual General Meeting of Shareholders. The Board of Directors must have such the balance sheet and profit and loss account audited by an auditor before proposing them to the Shareholders' Meeting.

The Board of Directors caused the financial statements for the year ended 31 December 2025 and had been audited by the Company's auditor and reviewed by the Audit Committee. The financial statements were presented in the Annual Registration Form (56-1 One Report) for the year 2025 which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, Board of Directors had approved and deemed it appropriate to propose the financial statements for the year ended 31 December 2025.

Significant financial information for the year 2025

1. The Group had total revenues from sales and services for the year 2025 amounting to Baht 1,010.22 million, which 22.5% increased from year 2024. As a result, gross profit margin rose up from 37.0% in 2024 to 40.1% in 2025. For net profit margin, the Group had turnaround net

(Translated)

profit margin from (3.9%) in 2024 to 4.3% in 2025. These were primarily resulted from two factors i.e. growth of gross profit and revenues

2. Financial position of 2024 and 2025 showed that the Company had higher assets and liabilities since the acquisition of land buildings from connected persons during 2025
3. The Company had cash flows from operating activities for 2025 amounting to Baht 130.94 million, which was insignificantly different from 2024. Whilst, cash paid from investing activities was Baht 277.38 million and cash received from financing activities was Baht 164.99 million resulted from acquisition of land and buildings from connected persons during the year 2025.

Executive Vice President of Finance and Accounting (CFO) then gave the shareholders an opportunity to raise questions about the financial statements for the year ended 31 December 2025.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: Approved the financial statements for the year ended 31 December 2025 with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	342,782,308	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	342,782,308	100.00000

Agenda 3 To Consider Approving the Appropriation of Net Profit to be Legal Reserve for the Performance for the Year Ended 31 December 2025 and Dividend Payment for the Year 2025

The Chairman assigned Dr. Sittichai Daengprasert; Group President, to report the appropriation of net profit to be legal reserve for the performance for the year ended 31 December 2025 and the dividend payment for the year 2025.

(Translated)

Group President explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider appropriating profits and fund as reserve fund, and Article 52 of the Company's Articles of Association and Section 116 of the Public Limited Companies Act, B.E. 2535 (1992), prescribe that the Company must appropriate part of its annual net profit as a reserve fund in the amount not less than 5% of the annual net profit less accumulated loss brought forward (if any) until this reserve fund reaches the amount not less than 10% of the registered capital.

In addition, Article 49 of the Company's Articles of Association prescribes that dividend payment may not be announced unless it is pursuant to the resolution of the Shareholders' Meeting, and Section 115 of the Public Limited Companies Act, B.E. 2535 (1992), prescribes that dividend payment must be approved by the shareholders' meeting.

The Company has policy to pay dividend at the rate not less than 40% of the net profit according to the Company's separate financial statements after deduction of all reserve funds as stipulated by law and Company's Articles of Association. However, such dividend payment must not exceed the retained profit according to the Company's separate financial statements. In addition, in the case that the Company's financial statements have accumulated deficit, the Company will not consider making dividend payment. The Company may consider paying dividend at the rate lower than the abovementioned rate depending on the Company's performance, financial position and liquidity, as well as the necessity to utilise the working capital for its business operation, the Company's future business expansion plan and other factors relating to the Company's management as deemed appropriate by the Board of Directors.

According to the performance for the year ended 31 December 2025, the Company had net profit and retained earnings reported in separate financial statements amounting to Baht 60,981,280.61 and Baht 36,180,872.40, respectively. The Board of Directors therefore rendered an approval resolution and deemed it appropriate to propose that the the Shareholders' Meeting consider approving the appropriation of net profit as legal reserve amounting to Baht 3,049,060.93. In addition, the Company proposed annual dividend for the year 2025 via cash at the rate of Baht 0.10 per share, totalled Baht 47,462,346.21. The annual dividend comprised interim dividend paid in September 2025 at the rate of Baht 0.0526 per share, totalled Baht 24,962,346.21, and remainder dividend proposed to Board of Directors' meeting no. 1/2026 at the rate of Baht 0.0474 per share, totalled Baht 22,500,000. Therefore, dividend payout ratio was 71.43% which was in line with the Company's dividend policy. The Company determines date of shareholders listing who entitle to the final dividend payment on 29 April 2026 and final dividend will be paid on 15 May 2026. Details of dividend payment were illustrated in the next page:

(Translated)

Summary of dividend payment of the Company

	Year 2025 (Proposed)	Year 2024 (Previous)
Net profit (loss) for the year (Baht)	60,981,218.61	(34,973,563.09)
Number of shares issued and paid-up (shares)		
- Interim dividend	474,574,921	474,554,900
- Proposed dividend	474,574,934	474,574,921
Dividend paid (Baht)		
- Interim dividend	24,962,346.21	14,995,741.96
- Proposed dividend	22,500,000.00	- None -
Total dividend paid	47,462,346.21	14,995,741.96
Dividend per share (Baht per share)		
- Interim dividend	0.0526	0.0316
- Proposed dividend	0.0474	- None -
Total dividend per share	0.10	0.0316
Earnings (losses) per share (Baht per share)	0.14	(0.074)
Dividend payout ratio	71.43%	- None -
Remark: Information excerpted from separate financial statements for the year ended 31 December 2025 (Audited)		

Group President then gave the shareholders an opportunity to raise questions about the appropriation of net profit as legal reserve for the performance for the year ended 31 December 2025 and the annual dividend payment for the year 2025.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: Approved the appropriation of net profit to be the legal reserve, and the annual dividend payment for the year 2025, with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	342,782,308	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	342,782,308	100.00000

(Translated)

Agenda 4 To Consider Approving the Appointment of Directors in Place of Directors who are to be Retired by Rotation

The Chairman explained to the Meeting that, at the Annual General Meeting of Shareholders for the year 2026, there are 4 directors who are to retire by rotation as follows:

- | | | |
|-----|-----------------------------------|----------------------|
| (1) | Asst. Prof. Lalita Hongratanawong | Independent Director |
| (2) | Mr. Natthawut Viboonpattanawong | Independent Director |
| (3) | Mr. Pissanu Daengprasert | Director |
| (4) | Mr. Tawat Kitkungvan | Director |

The Chairman asked directors to retire by rotation to leave from the meeting room. Such directors will attend the Meeting after this agenda has completed.

The Chairman explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider electing the directors in place of directors retiring by rotation, and Article 18 prescribes that, at every Annual General Meeting of Shareholders, at least one-thirds of the directors shall retire from office. If their number is not a multiple of three, then the number nearest to one-thirds shall retire from office. The directors who have been in office longest shall retire. A retiring director is eligible for re-election.

In this appointment of directors in place of directors retiring by rotation, the Nomination and Remuneration Committee considered it and concluded that the nominated directors were considered in compliance with the Company's nomination procedures, had qualifications in accordance with the related rules and appropriate for the Company's business operation. Additionally, the nomination of director of the Company considers variety in board structure and takes relevant skills as per Board Skill Matrix into account, together with other appropriate qualifications and align with the Company's strategies, both short-run and long-run, without limit to gender, race, religion. The nominated person shall not have prohibited characteristics under the laws and good corporate governance principle for listed companies.

Furthermore, the individuals to be nominated as independent directors had qualifications in accordance with the law on the requirements of independent directors. Profiles of the abovementioned directors are shown in the Detailed Profiles of the Candidates to be Elected as Directors in Place of Directors Retiring by Rotation delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 2).

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2026, during 16 September 2025 to 1 November 2025. However, no candidate was nominated by the shareholders.

(Translated)

The Board of Directors, excluding of directors who had interest, was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting consider approving the re-appointment of 4 retiring directors for another term.

The Chairman of the Nomination and Remuneration Committee then gave the shareholders an opportunity to raise questions about the appointment of directors to replace those retiring by rotation.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item. The election will be conducted on individual basis where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: Approved the appointment all 4 directors who were to be retired by rotation, with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

		Asst. Prof. Lalita Hongratanawong	Mr. Natthawut Viboonpattanawong	Mr. Pissanu Daengprasert	Mr. Tawat Kitkungvan
		Independent Director	Independent Director	Director	Director
Approved	Number of Votes	324,782,308	324,782,308	324,782,308	324,782,308
	Percentage	100.0000	100.0000	100.0000	100.0000
Disapproved	Number of Votes	0	0	0	0
	Percentage	0.0000	0.0000	0.0000	0.0000
Abstained	Number of Votes	0	0	0	0
	Percentage	Not included as base for voting calculation	Not included as base for voting calculation	Not included as base for voting calculation	Not included as base for voting calculation
Invalid Ballot(s)	Number of Votes	0	0	0	0
	Percentage	0.0000	0.0000	0.0000	0.0000
Total votes of the Meeting	Number of Votes	324,782,308	324,782,308	324,782,308	324,782,308
	Percentage	100.0000	100.0000	100.0000	100.0000

The said appointed directors returned to the meeting room.

(Translated)

Agenda 5 To Consider Approving the Determination of Remuneration of Directors and Subcommittees for the Year 2026

The Chairman asked Asst. Prof Lalita Hongratanawong, the Chairman of the Nomination and Remuneration Committee, to explain the determination of remuneration of directors and subcommittees for the year 2026.

The Chairman of the Nomination and Remuneration Committee explained to the Meeting that under Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider determining the remuneration of directors, and Article 34 prescribes that the reward and remuneration of directors shall be fixed by the Shareholders' Meeting. Accordingly, it was deemed appropriate to propose that the Shareholders' Meeting consider approving the determination of remuneration of directors and subcommittees for the year 2026. Whereby, directors' remunerations shall not aggregately exceed than 0.25% of total revenue according to the Company's consolidated financial statements as detailed below.

(a) Directors' meeting allowances and quarterly remunerations:

Types of Directors	Directors' Meeting	Quarterly
	Allowances (Baht Per Time)	Remunerations (Baht Per Quarter)
Chairman of the Board of Directors	40,000	15,000
Director and Independent Director	15,000	-
Chairman of the Audit Committee	30,000	10,000
Member of the Audit Committee	15,000	-
Chairman of the Risk Management Committee	12,000	-
Member of the Risk Management Committee	10,000	-
Chairman of the Nomination and Remuneration Committee	12,000	-
Member of the Nomination and Remuneration Committee	10,000	-

(b) Bonus: The Company shall pay directors' bonus by assigning the Board of Directors to determine criteria, details and bonus rate as appropriate. The Company shall pay directors' bonus from total directors' remunerations less total directors' meeting allowances and quarterly remunerations incurred until the the end of financial year.

(c) The directors' remuneration mentioned in part (a) and (b) shall not apply to directors who are the Company's executives which receive monthly remuneration.

(d) There is neither other remunerations nor other benefits paid to the directors

(Translated)

The Company had criteria and procedures to determine directors' remuneration as follow:

- (1) Consider thoroughly and filtered base on appropriateness
- (2) Compare with reference to average directors' remuneration in similar industry
- (3) Consider the Company's business and profit growth
- (4) Economic conditions
- (5) Current number of the Company's directors

The Board of Directors was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting for consideration and approval of the determination of remuneration of directors and subcommittees for the year 2026 as proposed.

The Chairman of the Nomination and Remuneration Committee then gave the shareholders an opportunity to raise questions about the determination of remuneration of directors and subcommittees for the year 2026.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution shall be passed by votes of no less than two-thirds of the total number of votes of the shareholders attending the Meeting.

Resolution: Approved the determination of remuneration of directors and subcommittees for the year 2026, with the unanimous vote of all votes of the shareholders who attended the Meeting, as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	342,782,308	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	342,782,308	100.00000

(Translated)

Agenda 6 To Consider Approving the Appointment of Company's Auditors and Specification of Auditors' Remuneration for the Year 2026

The Chairman explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider and appoint an auditor and determine the auditor's remuneration; Article 60 prescribes that the Annual General Meeting of Shareholders must appoint an auditor every year and may re-elect any such retired auditor to resume their position, and Article 61 prescribes that the Annual General Meeting of Shareholders must determine the auditor's remuneration. Therefore, it was deemed appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and specification of auditor's remuneration for the year 2026.

The Audit Committee had considered the appointment of auditor and specification of auditor's remuneration by considering professional expertise, independence, knowledge, experiences and ability to provide good value advices. Since the Company has engaged with the same audit firm for extended periods, the Audit Committee reviewed and concluded that to obtain new perspectives and practices, it is deemed appropriate to propose PricewaterhouseCoopers ABAS Ltd.; which have expertise, appropriate audit fees and independence, as an auditor in place of KPMG Phoomchai Audit Ltd. according to the details as follows:

- | | |
|-----------------------------------|--|
| (1) Ms. Rodjanart Banyatananusard | Certified Public Accountant No. 8435; or |
| (2) Ms. Wanvimol Preechawat | Certified Public Accountant No. 9548; or |
| (3) Mr. Kan Tanthawirat | Certified Public Accountant No. 10456, |

In case of the said auditors were unable to perform the works, PricewaterhouseCoopers ABAS Ltd. will provide other auditors from the same company who have the qualifications and do not have prohibited characteristics as prescribed by law, to audit and certify the Company's financial statements. The Audit Committee specified the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31 December 2026 in the amount not exceeding Baht 2,075,000 (excluding out of pocket expenses and VAT (if any)). Profiles and experiences of the abovementioned auditors are shown in the Detailed Profiles and Experiences of Auditors for the Year 2026 as delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 3). Detailed of auditor's remuneration was illustrated in the Annual Registration Form (56-1 One Report) for the year 2025, Topic "Auditor and its affiliates' remuneration" which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1).

All of the Company's subsidiaries use the same audit office to audit and certify the financial statements. The Board of Directors will oversight to ensure that the subsidiaries will prepare financial statements in a timely manner. In addition, the said auditors and audit office do not have any relationship and/or interest with the Company, subsidiaries, executives, major shareholders or related persons thereof.

(Translated)

The Board of Directors was in favor of the Audit Committee's proposal, and therefore, resolved to approve and deemed it appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and the specification of auditor's remuneration for the year 2026 as proposed.

The Chairman of the Audit Committee gave the shareholders an opportunity to raise questions about the appointment of Company's auditors and specification of auditors' remuneration for the year 2026.

Since no shareholder had any question, the moderator asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

Resolution: Approved the appointment of (1) Ms. Rodjanart Banyatananusard Certified Public Accountant No. 8435, or (2) Ms. Wanvimol Preechawat Certified Public Accountant No. 9548, or (3) Mr. Kan Tanthawirat Certified Public Accountant No. 10456, from PricewaterhouseCoopers ABAS Ltd., or other auditors from the same company, which have qualifications and do not have characteristics as restricted by the laws, to audit and certify the Company's financial statements, and specify the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31 December 2026 in the amount not exceeding Baht 2,075,000 (excluding out of pocket expenses and VAT (if any)), with the unanimous vote of the shareholders who attended the Meeting and cast their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	342,782,308	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	342,782,308	100.00000

Agenda 7 **Other Business (if any)**

The Chairman gave the shareholders an opportunity to raise questions or propose agenda items other than those shown in the agenda.

(Translated)

No shareholder raised any question or proposed any other agenda item. The Chairman therefore thanked the shareholders, directors, executives and other team members and declared the Meeting closed.

The Meeting adjourned at 11.18 AM.

(Ms. Sopawadee Lertmanaschai)

Chairman of the Meeting

(Ms. Jirada Daengprasert)

Company Secretary